AbbVie's Upadacitinib RINVOQ Receives Positive CHMP Opinion For Non-Segmental Vitiligo, Expected To Be First Systemic Medication For Condition

뉴스 본문을 불러오고 있어요.

AbbVie's Upadacitinib RINVOQ Receives Positive CHMP Opinion For Non-Segmental Vitiligo, Expected To Be First Systemic Medication For Condition | 웨이프 WAPE

AbbVie's Upadacitinib RINVOQ Receives Positive CHMP Opinion For Non-Segmental Vitiligo, Expected To Be First Systemic Medication For Condition

기사 요약

관련 종목

댓글 —